Sign In
Buy MCRB
$7.17
-0.160 (-2.18%)
At Close: Jun 03, 2026
Price T Rowe Associates Inc. MD Has $33.10 Million Stock Holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB)
01:42pm, Wednesday, 17'th Nov 2021 Transcript Daily
Price T Rowe Associates Inc. MD trimmed its position in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 2.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,387,839 shares of the biotechnology companys stock after selling 29,503 shares during the period. Price T Rowe Associates []
Commodore Capital Lp Buys Dicerna Pharmaceuticals Inc, IVERIC bio Inc, Merus NV, Sells , ...
03:38pm, Tuesday, 16'th Nov 2021 GuruFocus
Related Stocks: ISEE , ACRS , VRDN , KURA , PTGX , VTGN , DRNA , MRUS , TNYA , IOVA , RVMD , CNST , MGNX , EPIX , MRSN , MCRB ,
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2021 Results - Earnings Call Transcript
12:09pm, Wednesday, 10'th Nov 2021
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2021 Results - Earnings Call Transcript
Seres Therapeutics (MCRB) Q3 Earnings and Revenues Beat Estimates
09:57am, Wednesday, 10'th Nov 2021
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 253.19% and 1681.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the sto
Red Light For Seres Therapeutics, But Not A Stop Light For Me
09:08am, Wednesday, 10'th Nov 2021
Red Light For Seres Therapeutics, But Not A Stop Light For Me
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcas
BiomX: Undervalued With Multiple Upcoming Catalysts
06:42pm, Wednesday, 06'th Oct 2021
BiomX: Undervalued With Multiple Upcoming Catalysts
Seres Therapeutics Molecular Data On SER-109 Looks Good
08:30am, Monday, 04'th Oct 2021
Seres Therapeutics Molecular Data On SER-109 Looks Good
Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021
01:15pm, Saturday, 02'nd Oct 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced late-breaking data from its Phase 3 ECOSPOR III study evaluating
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from its Phase 3 ECOSPOR III study evaluating SER-109, an in
Why Seres Therapeutics Stock Is Soaring Today
03:35pm, Wednesday, 15'th Sep 2021
The company completed its target enrollment in a pivotal clinical study.
Why Seres Therapeutics Shares Are Trading Higher Today
03:25pm, Wednesday, 15'th Sep 2021
Seres Therapeutics (NASDAQ:MCRB) shares are trading higher after the company achieved enrollment of 300 subjects in its Phase 3 ECOSPOR IV study of SER-109. Seres Therapeutics' stock has been rising
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has achieved enrollment of 300 subjects with the ECOSPOR IV op
Seres Therapeutics: Here We Go Again
03:17pm, Thursday, 09'th Sep 2021
The microbiome has arrived as a significant area of opportunity for new treatments of infectious and chronic conditions. While the importance of the microbiome is clear, validated products remain elus
Cathie Wood's ARK Invest Sells Over 840,000 Shares of Seres Therapeutics
08:35am, Tuesday, 31'st Aug 2021
One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood sold over 840,000 shares of Seres Therapeutics Inc.
